| Year |
Citation |
Score |
| 2021 |
Nathansen J, Lukiyanchuk V, Hein L, Stolte MI, Borgmann K, Löck S, Kurth I, Baumann M, Krause M, Linge A, Dubrovska A. Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. Oncogene. PMID 34079088 DOI: 10.1038/s41388-021-01842-1 |
0.78 |
|
| 2019 |
Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova I, Negro G, Aschenbrenner B, Eisenhofer G, Richter S, Heiden S, Porrmann J, Klink B, ... ... Hein L, et al. The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30670494 DOI: 10.1158/1078-0432.Ccr-18-2951 |
0.476 |
|
| 2016 |
Peitzsch C, Cojoc M, Hein L, Kurth I, Mӓbert K, Trautmann F, Klink B, Schrock E, Wirth MP, Krause M, Stakhovsky EA, Telegeev GD, Novotny V, Toma MI, Muders M, et al. An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells. Cancer Research. PMID 26984757 DOI: 10.1158/0008-5472.Can-15-2116 |
0.662 |
|
| 2015 |
Kurth I, Hein L, Mäbert K, Peitzsch C, Koi L, Cojoc M, Kunz-Schughart L, Baumann M, Dubrovska A. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget. PMID 26460734 DOI: 10.18632/Oncotarget.5417 |
0.71 |
|
| 2015 |
Kuhlmann JD, Hein L, Kurth I, Wimberger P, Dubrovska A. Targeting cancer stem cells: promises and challenges. Anti-Cancer Agents in Medicinal Chemistry. PMID 26179271 DOI: 10.2174/1871520615666150716104152 |
0.771 |
|
| 2015 |
Mladenov R, Hristodorov D, Cremer C, Hein L, Kreutzer F, Stroisch T, Niesen J, Brehm H, Blume T, Brümmendorf TH, Jost E, Thepen T, Fischer R, Stockmeyer B, Barth S, et al. The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. International Journal of Cancer. Journal International Du Cancer. 137: 2729-38. PMID 26041304 DOI: 10.1002/ijc.29628 |
0.328 |
|
| 2010 |
Clere N, Corre I, Faure S, Guihot AL, Vessières E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. International Journal of Cancer. Journal International Du Cancer. 127: 2279-91. PMID 20143398 DOI: 10.1002/Ijc.25234 |
0.366 |
|
| Show low-probability matches. |